KeyBanc Trims Target but Stays Bullish on Oddity’s Beauty-Tech Play
The firm emphasized that Oddity remains in the early innings of a high-growth story, with potential upside driven by its proprietary hyperspectral + biotech stack and the upcoming Q4 launch of a medical...









